Krebs Biochemicals & Industries Ltd (KREBSBIO) — shareholding pattern, promoter holding, financials and share price
About Krebs Biochemicals & Industries Ltd (KREBSBIO)
Krebs Biochemicals & Industries Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KREBSBIO and on the BSE under scrip code 524518. Its ISIN is INE268B01013.
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
Krebs Biochemicals & Industries Ltd specializes in manufacturing Active Pharmaceutical Ingredients using a unique fermentation process. It is among a few globally employing this method.
The company is engaged in biotechnology, applying its processes in medicine, agriculture, and industry. This includes contract manufacturing for large multinational companies.
Listed peers in Pharmaceuticals: Lactose (India) Ltd, Tyche Industries Ltd, Godavari Drugs Ltd, Pharmaids Pharmaceuticals Ltd, Sotac Pharmaceuticals Ltd, Par Drugs & Chemicals Ltd.
Valuation & Returns
10 Jul 2026At ₹54.91 a share on 10 Jul 2026, Krebs Biochemicals & Industries Ltd (KREBSBIO) was valued at a price-to-earnings ratio of -6.99x against an industry P/E of 36.41x. Solomo computes return on equity of 10.4% and return on capital employed of -14.93% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -6.99x
- Industry P/E
- 36.41x
- EPS (TTM)
- ₹-7.85
- Book value / share
- ₹-67.83
- ROE
- 10.4%
- ROCE
- -14.93%
- ROA
- -10.02%
- Debt / equity
- -1.38x
- Dividend yield
- 0%
- EBITDA margin
- -14.45%
- 52-week range
- ₹38.52 – ₹84.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Krebs Biochemicals & Industries Ltd (KREBSBIO) reported revenue of ₹24 crore, net profit of ₹-17 crore and earnings per share of ₹-7.85. That compares with revenue of ₹43 crore and net profit of ₹-27 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹6.81 crore and net profit ₹-2.34 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 60 | 52 | 50 | 43 | 24 |
| Net profit (₹ cr) | -45 | -25 | -20 | -27 | -17 |
| EPS (₹) | -20.65 | -11.45 | -9.15 | -12.5 | -7.85 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 46.31% | 5.33% | -10.15% | -14.10% |
| Profit growth | - | - | - | -36.54% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.74% of Krebs Biochemicals & Industries Ltd (KREBSBIO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.5%. Market capitalisation was ₹118 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SUN PHARMACEUTICAL INDUSTRIES LTD 4.81%, GUTTIKONDA RAJASEKHAR 1.86%, GUTTIKONDA VARA LAKSHMI 1.7%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.74% | - | 0.5% | - | 27.26% |
| Mar 2026 | 72.74% | - | 0.5% | - | 27.26% |
| Dec 2025 | 72.74% | - | 0.5% | - | 27.26% |
| Sep 2025 | 72.74% | - | 0.5% | - | 27.26% |
| Jun 2025 | 72.74% | - | 0.5% | - | 27.26% |
| Mar 2025 | 72.74% | - | 0.5% | - | 27.26% |
| Dec 2024 | 72.74% | - | 0.5% | - | 27.26% |
| Sep 2024 | 72.74% | - | 0.5% | - | 27.26% |